Since AD is a neurological disease that requires chronic treatment, we performed a chronic-dosing four-week study to determine the impact of continuous TfRMAb treatment on CBC indices, brain TfR levels, plasma and brain iron levels, plasma PK of TfRMAb, and overall health of the mice. This evidence concerns the gene TFRC and Alzheimer disease.